Angeles County, CA; New York, NY; and St. Paul, MN) between July 2000 and August 2002. Participants were excluded if they had physician-diagnosed cardiovascular disease prior to enrollment, including angina, myocardial infarction, heart failure, stroke or TIA, resuscitated cardiac arrest or a cardiovascular intervention (e.g., CABG, angioplasty, valve replacement, or pacemaker/defibrillator placement). Pre-specified recruitment plans identified four racial/ethnic groups (non-Hispanic European American, African American, Hispanic American, and Chinese American) for enrollment, with targeted oversampling of minority groups. Race was self-reported. The institutional review boards at each participating institution approved MESA and each individual participant provided informed written consent prior to enrollment.
Ascertainment for ESP sequencing study: As part of the HeartGO component of the ESP, DNA from 424 participants was sent to both sequencing centers for exome sequencing. MESA contributed samples and data to analysis of blood pressure, LDL, ischemic stroke, obesity/diabetes and the deeply phenotyped reference group.
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C. The Women's Health Initiative (WHI)
WHI is one of the largest (n=161,808) studies of women's health ever undertaken in the U.S. There are two major components of WHI: (1) a Clinical Trial (CT) that enrolled and randomized 68,132 women ages 50-79 into at least one of three placebo-control clinical trials (hormone therapy, dietary modification, and calcium/vitamin D); and (2) an Observational Study (OS) that enrolled 93,676 women of the same age range into a parallel prospective cohort study. A diverse population, were recruited including 26,045 (17%) women from minority groups from 1993-1998 at 40 clinical centers across the U.S. For the CT and OS participants enrolled in WHI and who had consented to genetic research, DNA was extracted by the Specimen Processing Laboratory at the Fred Hutchinson Cancer Research Center (FHCRC) from specimens that were collected at the time of enrollment in the study between 1993 and 1998.
Ascertainment for ESP sequencing study: As part of the WHI Sequencing Project (WHISP) component of ESP, DNA from 2,195 participants were sent to both sequencing centers for exome sequencing. WHI contributed samples and data to analysis of blood pressure, LDL, body mass index, type 2 diabetes, early-onset MI, ischemic stroke, and the deeply phenotyped reference group. D. Other EOMI Studies 1. Cleveland Clinic GeneBank (CCGB) was a single-center prospective cohort-based study that enrolled individuals undergoing elective diagnostic coronary angiography between 2001 and 2006. Coronary artery disease (CAD) was defined as adjudicated diagnoses of stable or unstable angina, MI (adjudicated definition based on defined electrocardiographic changes or elevated cardiac enzymes), angiographic evidence of ≥ 50% stenosis of one or more major epicardial vessel, and/or a history of known CAD (documented MI, CAD, or history of revascularization).
Ascertainment for ESP sequencing study:
For the ESP EOMI study, 35 cases were from the CCGB study.
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2. Heart Attack Risk in Puget Sound (HARPS) was a population-based case-control study that enrolled cases with incident MI presenting to a network of hospitals in Washington State between 1991 and 2002. In HARPS, eligible cases were men with MI at age less than 50 and women with MI at age less than 60.
Ascertainment for ESP sequencing study: For the ESP EOMI study, 406 cases were selected from the HARPS study. 3. Massachusetts General Hospital -Premature Coronary Artery Disease (MGH-PCAD) was a hospital-based case-control study that enrolled cases hospitalized with MI at MGH between 1999 and 2004. In MGH-PCAD, eligible cases were men with MI at age less than 50 and women with MI at age less than 60.
Ascertainment for ESP sequencing study: For the ESP EOMI study, 155 cases were drawn from the MGH-PCAD study. 
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E. Other Stroke Studies 1. The Ischemic Stroke Genetics Study (ISGS)
The Ischemic Stroke Genetics Study (ISGS) was supported to perform a prospective genetic association study of ischemic stroke focusing on the hemostatic system. ISGS was a 5-center case-control study of first-ever ischemic stroke cases and concurrent controls individually matched for age, sex and recruitment site. This study utilized the NINDS Repository Cerebrovascular/Stroke Study, and neurologically normal controls from the sample population which are banked in the National Institute of Neurological Disorders and Stroke (NINDS Repository) collection for a first stage whole genome analysis. The number of study subjects that have individual level data available through Authorized Access is 485.
Ascertainment for ESP sequencing study: Seventy-five ischemic stroke cases (37 African American and 39 European American) were selected for sequencing in ESP.
ISGS Study Case eligibility criteria:
Ischemic stroke was diagnosed according to World Health Organization definition by history and physical examination, as well as by and findings on brain imaging (either head computed tomography or magnetic resonance imaging). Subjects were eligible cases if they were over the age of 18 years and had a first-ever ischemic stroke with onset of symptoms within 30 days of enrollment. The study excluded cases with postoperative or post-procedural stroke (i.e., stroke related to cardiac catheterization, carotid stenting or conventional cerebral angiography); stroke related to recent subarachnoid hemorrhage or mechanical heart valve (aortic or mitral); individuals with known inherited stroke syndromes (CADASIL, MELAS, Fabry disease, homocysteinemia, sickle cell anemia); and individuals with biopsy-proven central nervous system vasculitis or stroke occurring in the setting of active bacterial endocarditis.
ISGS Study Control Eligibility criteria:
Controls were volunteers over the age of 18 years who have been verified stroke-free by structured interview. This study excluded volunteers who were considered unreliable historians, who had a blood relative enrolled as a case; and who were inpatients being treated for coronary or peripheral vascular disease. Controls needed to answer negatively on all the items of the Questionnaire for Verifying Stroke-Free Status.
Ascertainment for ESP sequencing study: Seventy-eight early onset small vessel and large vessel Trial of Org 10172 in Acute stroke Treatment (TOAST) subtype cases were selected for sequencing. 
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C. Siblings with Ischemic Stroke (SWISS)
The Siblings with Ischemic Stroke Study (SWISS) was supported to perform an affected sib-pair (ASP) linkage and family-based genetic association study of ischemic stroke focusing on the hemostatic system. The number of study subjects that have individual level data available through Authorized Access is 100 phenotyped subjects.
Probands were recruited at 70 US and Canadian medical centers. Probands were adult (>18 years old) men and women presenting to a participating center with a study neurologist-confirmed ischemic stroke. Stroke was defined as rapidly developing signs of a focal or global disturbance of cerebral function, with symptoms lasting at least 24 hours or leading to death, with no apparent cause other than vascular origin (World Health Organization definition). Stroke was defined as ischemic when computed tomography or magnetic resonance imaging of the brain was performed within 7 days of onset of stroke symptoms and identified the symptomatic cerebral infarct or failed to identify an alternative cause of symptoms. Probands were required to have reported at least one living full sibling with a history of stroke. No probands were enrolled with iatrogenic vasospastic or vasculitic stroke or if the stroke occurred in the setting of a mechanical heart valve or in the setting of untreated or actively treated bacterial endocarditis. Probands were also excluded if they were known to have CADASIL, Fabry disease, homocysteinuria, MELAS, or sickle-cell anemia. Study neurologists at each center assigned to the qualifying ischemic stroke of each proband TOAST subtype diagnosis. Stroke-affected siblings of the proband (concordant siblings) were recruited by using proband-initiated contact. Telephone interviews were performed to obtain demographic and clinical information and to gain permission for obtaining medical records pertaining to treatment for stroke. Medical records were compiled and adjudicated by a central committee to verify the diagnosis of ischemic stroke and to assign a TOAST subtype diagnosis. Unaffected siblings were ascertained by telephone contact and interview.
Ascertainment for ESP sequencing study: Ninety-four affected sib-pairs with TOAST sub-type diagnosis of European American were selected for sequencing. 
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Early-Onset Myocardial Infarction (EOMI)
EOMI cases and controls were selected from ten studies, including ARIC, CCGB, FHS, HARPS, MGH-PCAD, PennCATH, TRIUMPH, WHI, CHS, and JHS. We ascertained 1,090 cases with MI at an early age. Early onset myocardial infarction (EOMI) cases were defined as individuals who had experienced an incident MI at age ≤ 60 years in women or ≤ 50 years in men. As a comparison group, we selected 979 participants from prospective cohort studies who were free of MI despite advanced age. Controls were selected as individuals with no history of MI at baseline or during follow-up to at least age 60 for men and 70 for women. Controls were also selected as having the highest baseline calculated Framingham risk scores (selected in descending order). Approximately two-thirds of the EOMI sample was of European ancestry and one-third of African-American ancestry. By design, the cases were, on average, more than two decades younger than the controls. Thus, male cases suffered an MI on average at 44 years old whereas the average age for male controls was 73 years old.
For the ESP EOMI study, 129 cases were selected from the primary ESP population-based cohorts ARIC, FHS and MESA studies and 642 controls were drawn from the ARIC, CHS, FHS, JHS and MESA studies. From WHI, 21 African American and 138 European American female MI cases age 60 or younger were selected. From the WHI study, 146 female cases and 305 female controls were selected. Among the prospective cohort studies, incident cases were defined by MI, coronary revascularization, hospitalized angina or CHD death, as adjudicated from medical record data by committee using standardized criteria. Additional cases meeting the EOMI criteria were selected from: HARPS (406 cases), a population-based case-control study that enrolled cases with incident MI in Washington State; MGH-PCAD (155 cases), a hospital-based MI case-control study; TRIUMPH (122 cases), an observational, multicenter prospective MI registry; PennCATH (36 cases), a catheterization-lab based coronary angiography cohort study from the University of Pennsylvania Medical Center; CCGB (35 cases), a single-center prospective cohort of individuals undergoing diagnostic coronary angiography. Among the angiography-based studies, coronary artery disease (CAD) was defined as adjudicated diagnoses of stable or unstable angina, MI (adjudicated definition based on defined electrocardiographic changes or elevated cardiac enzymes), angiographic evidence of ≥ 50% stenosis of one or more major epicardial vessel, and/or a history of known CAD (documented MI, CAD, or history of revascularization).
Ischemic Stroke
Stroke cases were selected from Heart-GO cohorts, WHISP and Siblings With Ischemic Stroke Study (SWISS) and the Ischemic Stroke Genetics Study (ISGS). HeartGO and WHISP stroke cases were defined as participants who had experienced an incident ischemic stroke that was subcategorized as either large vessel (atherosclerotic) or small vessel (lacunar) and falling into one of the following categories: stroke occurring by age 65 years and a positive family history of stroke, stroke occurring by age 65 years and no positive family history of stroke, or stroke occurring after age 65 years and a positive family history of stroke. Participants were excluded from selection if they had previously been selected for the EOMI or LDL studies. HeartGO stroke cases were selected from ARIC, CHS, FHS and MESA. From HeartGO, a total of 55 samples passed initial quality control and 53 samples (8 African American and 45 European American) generated finished sequence data. From WHISP, women who had experienced a large or small vessel ischemic stroke were considered for selection. Women were selected based on the following priorities, age <67 and/or a positive family history of stroke. A total of 278 samples passed quality control (36 African American and 242 European American). The following From the SWISS cohort, there were 98 affected sibpairs concordant for ischemic stroke TOAST subtype that passed QC and 94 provided completed exome sequence data. From the ISGS cohort, 94 unrelated ischemic stroke cases passed QC and 89 of these samples provided exome sequence data. Following exclusion due to IRB-sharing limitations, a total of 78 ISGS samples were available for analysis and deposition into dbGaP.
LDL-cholesterol
To enrich for individuals with rare large-effect size variants, we initially ascertained 412 individuals with extreme (high or low) LDL-C levels from ~25,000 population-based samples. The LDL-C extreme samples were selected initially from four population-based cohorts: ARIC, CHS, FHS and JHS. Samples previously selected as EOMI cases or controls were excluded from selection. In each cohort, first visit LDL-C was calculated using the Friedewald formula, based on HDL, triglyceride and total cholesterol measurements obtained in fasting subjects. For individuals on lipid lowering medication, pre-treatment LDL-C values were estimated by dividing treated LDL-C values by 0.75 to model a 25% reduction in LDL-C on therapy. Estimated pre-treatment LDL-C levels (or actual LDL-C levels for those not on lipid-lowering therapies) were then regressed on sex, age, and age-squared within cohort and within ethnicity strata (European-American and African-American). Residuals were then combined across studies, within ethnicity strata. The N=120 residuals in each ethnic stratum associated with the largest adjusted LDL-C values were selected. A corresponding number of individuals with the smallest adjusted LDL-C residuals were selected so that the number of extreme low LDL-C samples matched the number of extreme high LDL-C samples for each cohort. A second set of extreme LDL samples was selected from the CARDIA and MESA cohorts, using the same criteria that were used for the first set of LDL samples. The 412 selected samples roughly represent the 1st and 99 th percentiles for adjusted LDL in European-Americans and the 2 nd and 98 th percentiles in African-Americans. A total of 147 European Americans LDL High, 142 African Americans LDL High, 145 European Americans LDL Low, and 131 African Americans LDL Low samples were sequenced and passed initial quality control. An additional N=26/ N=27 respectively) were selected for sequencing. African American women whose residuals were in the 2 nd high/low European Americans samples and N=23/N=23 high/low African Americans samples were selected from WHI.
The extreme LDL-C samples were augmented with data from additional samples sequenced as part of ESP for other phenotypes from those with LDL-C measured and lipid-lowering medication status available (N=1593). The primary phenotypes for sample selection were EOMI and controls (individuals with no baseline or incident MI and with high estimated Framingham risk scores), ischemic stroke cases (large or small vessel ischemic stroke before age 65 or with positive family history), blood pressure extremes (1st and 99th sex-and decade-specific percentile tails), body mass index (high and low BMI), and a set of randomly selected samples among participants with near-complete phenotype data across a range of traits.
The total of 2,005 ESP samples were selected from seven population-based cohorts: ARIC, CARDIA, CHS, FS, JHS, MESA, and WHI. Of the 2,005 sequenced individuals, a total of 854 (43%) individuals were African-American and the remainder (N=1,151, 57%) were European-American.
Blood Pressure
Samples were selected for the blood pressure study based on blood pressure measurements from all available visits. Participants were excluded from selection if they had previously been selected for another ESP phenotype, had a history of MI or heart failure at baseline, or age<20 or >70 years. Blood pressure measurements from visits with concurrent or a prior visit report of incident MI, CHF or BMI measurement > 4 standard deviations from the mean were excluded from selection eligibility. At each eligible visit, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were adjusted for self-report of hypertension medication use. Both SBP and DBP were then regressed on age, age^2, BMI, sex, and self-identified--, within cohort. The sum of the standardized residuals (summing across SBP and DBP residuals) was used for selection. Individuals with sum of standardized residuals in the 1 st and 99 th self-identified-race-, sex-, and age category-specific (based on decade) percentiles at any visit were selected for sequencing. HeartGO blood pressure samples were selected from the ARIC, CARDIA, CHS, FHS, JHS and MESA cohorts. 
Body Mass Index (BMI)
For the body mass index (BMI) study, 217 lean (BMI between 18 and 25) non-diabetic women were selected along with 163 morbidly obese (BMI over 40) diabetic women and 163 morbidly obese non-diabetic women were selected from WHI. An extra 70 morbidly obese women were added regardless of diabetes status. All women in the BMI study were of African American ethnicity. High body mass index (BMI) samples were additionally selected from the CARDIA, JHS and MESA cohorts. Samples were restricted to female African American participants who had not previously been selected for another ESP phenotype, and with first visit BMI measurement of at least 45, regardless of type 2 diabetes status. A total of 144 African American HeartGO BMI samples were sequenced and passed initial quality control.
Deeply Phenotyped Reference (DPR):
For the deeply phenotype reference (DPR) group, individuals were chosen based on availability of multiple heart, lung, and blood phenotypes. Eligibility for sample selection was determined using the following criteria: participants had to have non-missing data for the majority of a range of baseline cardiovascular-related phenotypes measured in each cohort (>95% of each sample) and had not been selected previously for another ESP phenotype. Samples were selected from the ARIC, CARDIA, CHS, FHS, JHS and MESA cohorts so that the self-identified-race-specific sample sizes for each were proportional to the overall cohort sizes. Samples were then randomly selected from the pool of eligible participants within each cohort. A total of 431 European American samples and 124 African American samples from HeartGO cohorts were sequenced and passed initial quality control. An additional 95 African American and 311 European American women from WHI were selected for sequencing in the DPR group. 
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